The short answer
Methionine in a peptide oxidizes to methionine sulfoxide (Met(O), +15.995 Da). The thermodynamics are never the barrier, so "local redox potential" is the wrong frame. Oxidation of a thioether by Oβ is downhill under any condition a vial will see. What protects a peptide is kinetics: ground-state triplet Oβ reacts very slowly with closed-shell sulfides. The real culprits are reactive oxygen species. These come from peroxide impurities in excipients (polysorbates especially) [6,7], metal-catalyzed (Fenton-type) chemistry driven by trace Fe/Cu [4,5,8], and light (singlet oxygen and photo-sensitized radicals) [9]. Headspace Oβ and a leaky closure feed these chains, but they rarely cause oxidation directly. Cyclic voltammetry of Met is irreversible and adsorption-dependent [10], so it cannot give a thermodynamic EΒ° that predicts shelf life. LC-MS peptide mapping that tracks +16 Da species over time is the right tool.
Correcting the course framing
My CHEM102 notes said that the Nernst framework "provides the framework for understanding oxidative degradation of peptides (e.g., at methionine residues) driven by local redox potentials." CHEM102L went further and claimed Met/Trp susceptibility "is dictated by their standard reduction potentials." One research idea was to "investigate the Nernst equation parameters for methionine oxidation to predict the shelf-life impact of oxygen exposure."
That is a category error, and it's worth spelling out why.
- The Nernst equation describes equilibrium. It tells you whether a reaction can go and how far. For Met + Β½Oβ β Met(O) the equilibrium lies overwhelmingly on the product side, so the answer is always "yes, all the way." It says nothing about how fast. Shelf life is a rate question.
- "Solution redox potential" is ill-defined in a vial. A formulation is not a poised redox buffer. There is no reversible couple setting E_h, so a platinum electrode would read a mixed potential dominated by trace species. This is my reasoning, not a cited finding.
- The rate-limiting chemistry is spin and radical chemistry. Triplet Β³Oβ reacting with a singlet thioether is spin-forbidden, which is why air-saturated Met solutions survive for long periods without catalysts (general physical chemistry). The fast reactants are singlet species and radicals: HβOβ and organic hydroperoxides (two-electron oxygen transfer), Β·OH and ferryl species from metals, and ΒΉOβ from photosensitization [3,4].
- Real reactivity is set by structure. Solvent exposure, neighboring groups and local dynamics matter, not EΒ°. SchΓΆneich describes neighboring-group stabilization of both two-electron and one-electron oxidation pathways [3]. Li et al. showed that a histidine one residue away from Met markedly accelerated oxidation in model peptides [5]. A recent QM/MM + MD study concluded that "the protein's local and global motion represent the primary discriminating factor among residues' oxidation rates" [11].
The question the course should have asked: what oxidant flux reaches each Met, and from where?
The chemistry: what happens to methionine
METHIONINE OXIDATION PATHWAYS IN A PEPTIDE FORMULATION
ββββββββββββββββββββββββ
β MET (THIOETHER, R-S-CH3)β
βββββββ¬βββββββββββ¬ββββββββ
TWO-ELECTRON β β ONE-ELECTRON
(H2O2, ROOH, 1O2) β β (Β·OH, FERRYL, PHOTO)
β β
ββββββββββββββββββββ βββββββββββββββββββββββββ
β MET SULFOXIDE β β MET RADICAL CATION β
β +16 Da (R/S) β β (SΒ·+) β
ββββββββββ¬ββββββββββ ββββββββββββ¬βββββββββββββ
β STRONG OXIDANT β IRREVERSIBLE
β β
ββββββββββββββββββββ βββββββββββββββββββββββββ
β MET SULFONE β β C-CENTRED / PEROXYL β
β +32 Da (RARE) β β RADICALS β CHAIN β
ββββββββββββββββββββ β OXIDATION, FRAGMENTS β
βββββββββββββββββββββββββ
OXIDANT SOURCES: POLYSORBATE ROOH ββ Fe/Cu + O2 + REDUCTANT ββ LIGHT + SENSITIZER ββ
ββββββββββββ FEED BOTH BRANCHES βββββββββββββββββββββββ
Key facts:
- Met(O) is +15.995 Da. Oxidation creates a new stereocenter at sulfur, giving R and S diastereomers that sometimes resolve as two peaks on RP-HPLC.
- Two-electron oxidation gives the sulfoxide. One-electron oxidation gives a radical cation, which "will enter predominantly irreversible reaction channels, which ultimately yield carbon-centered and/or peroxyl radicals" and can start chain oxidation [3].
- Met(O) increases polarity. The oxidized peptide typically elutes earlier on reversed-phase HPLC. Oxidation in a helix-forming region can also disrupt structure and promote aggregation; Torosantucci et al. note oxidation "often leads to modifications of higher-order structures, including aggregate induction" [2].
- Other residues oxidize too. Li, SchΓΆneich and Borchardt list Met, Cys, His, Trp and Tyr as most susceptible [1]. Light preferentially attacks Trp, Tyr, Phe and Cys/cystine [9]. Trp oxidation gives a family of products (+4, +16, +32 Da: kynurenine, hydroxy-Trp, N-formylkynurenine; standard mass assignments in the field).
Mass-shift reference table (monoisotopic)
| Modification | Ξ mass (Da) | Notes |
|---|---|---|
| Met β Met sulfoxide | +15.995 | Most common; two diastereomers |
| Met β Met sulfone | +31.990 | Needs strong oxidants |
| Trp β kynurenine | +3.995 | Photo-oxidation marker |
| Trp β hydroxy-Trp / oxindolylalanine | +15.995 | Isobaric with Met(O); MS/MS needed |
| Trp β N-formylkynurenine | +31.990 | Isobaric with sulfone |
| Asn β Asp/isoAsp (deamidation) | +0.984 | Succinimide intermediate β17.027 |
| Diketopiperazine loss (N-terminal dipeptide) | β (dipeptide residue mass) | Truncation |
The +16 isobar is a practical trap. A +16 peak on intact-mass LC-MS of a Met- and Trp-containing peptide does not tell you which residue was hit. Only MS/MS fragmentation locates it.
Where the oxidants actually come from
1. Peroxides in excipients
Polysorbates 20 and 80 autoxidize, forming hydroperoxides, side-chain cleavage products and eventually short-chain acids such as formic acid [6]. Ha, Wang and Wang showed that "peroxides can be easily generated in neat polysorbate 80 in the presence of air during incubation at elevated temperatures." Formation was faster in aqueous solution and further promoted by light. Peroxides at higher levels oxidized a model protein in both liquid and solid states [7].
Most research peptides are sold as neat lyophilized powders without surfactant, so this pathway mostly matters downstream, when someone reconstitutes into a surfactant-containing buffer. The general lesson does carry over: any excipient with an ether or allylic structure (PEGs, polysorbates, some sugars after processing) can carry peroxide. Peroxide in excipient lots is a measurable spec.
2. Transition metals: the "leaching from equipment" question
This is the CHEM102 question, and the answer is yes, demonstrably. Lam, Yang and Cleland found that a NaCl-containing formulation of the HER2 antibody oxidized more after contact with stainless steel. "The corrosion of stainless steel by chloride ions at the low pH of the formulation buffer generated iron ions that catalyzed methionine oxidation" [8].
The mechanism is metal-catalyzed oxidation (MCO). Stadtman's review lays out the cycle: Fe(III)/Cu(II) is reduced by an electron donor, Oβ is reduced to HβOβ, and the products react at metal-binding sites on the protein to produce Β·OH or ferryl species that attack nearby side chains. Methionine ends up as Met(O) [4]. Three consequences follow:
- MCO is site-specific, not random. Residues near a metal-binding site (His, Asp/Glu clusters, the N-terminus) are hit preferentially [4].
- Antioxidants can backfire. A reductant such as ascorbate regenerates Fe(II) and drives the Fenton cycle. Li et al. showed that ascorbic acid promotes rather than inhibits Met oxidation with FeΒ³βΊ. In their system EDTA did not inhibit it either [5]. Li, SchΓΆneich and Borchardt's review warns that for metal-catalyzed oxidation "the addition of antioxidants may accelerate" it [1].
- Chloride at low pH plus stainless steel is a known bad combination [8]. Peptide TFA salts in solution are acidic, and HCl salts carry chloride. Whether that matters in SPPS cleavage and purification hardware is my open question. I found no peptide-specific study.
My inference on the "complex ions affect solubility" part of the question: metal binding to His/Asp/Glu can also bridge peptide molecules and nucleate aggregation, separately from oxidation. That needs testing, not assertion.
3. Light
Kerwin and Remmele review protein photodegradation. Primary photo-oxidation hits Trp, Tyr, Phe and Cys/cystine, and the resulting changes can alter higher-order structure [9]. Lam et al. found that light-induced Met oxidation in the HER2 antibody proceeded "via singlet oxygen pathway" while temperature-induced oxidation went via free radicals [8]. Different oxidant, different scavenger. A 2026 Novo Nordisk study found "significant disparity in strength, impurity sum, and high-molecular-weight protein level" between compounded semaglutide and originator products after light exposure [12]. That is directly relevant to grey-market and research-grade incretins.
4. Headspace oxygen and the closure
Here the "poorly sealed vial" part of the question belongs, reframed. A leaky closure does three things:
- It replenishes Oβ consumed by any radical chain. Without a catalyst, Oβ alone is slow, but it is the terminal oxidant that keeps MCO and autoxidation cycles running.
- It admits moisture. In a lyophilized cake, water plasticizes the matrix, increasing molecular mobility and reaction rates. Even a well-sealed butyl stopper transfers its own moisture into the product over months [13].
- It voids a nitrogen overlay. Nitrogen-flushed vials are only protected while integrity holds.
Container closure integrity (CCI) is measurable. Laser-based headspace gas analysis is a nondestructive, deterministic method that detects Oβ ingress into vialβstopper assemblies under diffusive or effusive leak conditions. USP β¨1207.1β© prefers deterministic methods [14].
Worked number (my calculation): a 3 mL vial with 2.5 mL headspace at 21% Oβ and 25 Β°C holds n = PV/RT = (0.21 Γ 101325 Γ 2.5Γ10β»βΆ)/(8.314 Γ 298) β 21 Β΅mol Oβ. A 5 mg vial of a 4.1 kDa peptide holds about 1.2 Β΅mol peptide. With one Met per molecule, the headspace alone has roughly 17Γ the Oβ needed to oxidize every Met. So Oβ is never stoichiometrically limiting in an air-filled vial, which confirms that the barrier is kinetic. Nitrogen overlay to under 1β2% residual Oβ cuts the reservoir about 10β20Γ, but even that is not stoichiometrically protective. It mostly slows the radical chains.
Can cyclic voltammetry predict shelf life?
Short answer: no, not usefully. CV can still help characterize mechanism.
Enache and Oliveira-Brett studied Met and Cys oxidation at glassy carbon and boron-doped diamond electrodes. The oxidation reactions "are irreversible, diffusion-controlled pH dependent processes, and occur in a complex cascade mechanism." At glassy carbon, Met oxidizes in two steps (sulfoxide, then sulfone) involving adsorption. At boron-doped diamond it is one step to sulfone because adsorption is negligible [10].
That has three consequences:
- Irreversible waves have no thermodynamic EΒ°. The peak potential depends on scan rate, electrode material and adsorption. It measures how fast electron transfer happens at that interface, not intrinsic susceptibility.
- Electrode electron transfer is not the same as reaction with HβOβ or ΒΉOβ. Electrode oxidation is outer-sphere-like or adsorption-mediated one-electron chemistry. Peroxide oxidation is two-electron oxygen-atom transfer. The two can rank residues differently. This is my inference, consistent with the mechanistic split described by SchΓΆneich [3].
- Accessibility dominates in folded or self-associated peptides. A Met buried in a semaglutide-like oligomer may resist peroxide yet still oxidize at an electrode after unfolding at the interface.
Where CV and electrochemistry are useful: as an electrochemical stress tool (controlled-potential generation of oxidation products for MS identification) and for detecting trace oxidants or metals in excipients. Enache and Oliveira-Brett also studied direct electrochemical oxidation of the repair enzyme methionine sulfoxide reductase A on carbon electrodes (Bioelectrochemistry 2013), which shows the method's reach. I did not read that paper beyond the title and don't cite it for a claim. For shelf-life prediction, forced degradation with HβOβ, AAPH (radical initiator), Fe/ascorbate and ICH-type light, read out by LC-MS, is the standard approach and much more informative.
Companion pathways: deamidation and diketopiperazines
Oxidation is rarely the only clock running. Two other covalent pathways deserve equal analytical attention.
Deamidation (AsnβGly hot spots)
Geiger and Clarke showed that the hexapeptide VYPNGA deamidates via an aspartyl succinimide with a half-life of only 1.4 days at 37 Β°C, pH 7.4. The succinimide then hydrolyzes (tΒ½ 2.3 h) to a mixture of L/D-Asp and isoAsp and racemizes (tΒ½ 19.5 h). Replacing Gly with Leu or Pro slowed degradation 33β50-fold [15]. Robinson and Robinson measured deamidation rates for 306 Asn sequences in model peptides at pH 7.4 and 37 Β°C, which gives a lookup table for sequence-dependent risk [16].
Mass signatures: succinimide β17.03 Da, Asp/isoAsp +0.98 Da. isoAsp and Asp are isobaric and need chromatographic separation or specific fragmentation to tell apart.
Worked example (my calculation): tΒ½ = 1.4 d means k = ln2/1.4 = 0.50 dβ»ΒΉ at 37 Β°C. Assume Ea β 80 kJ/mol (illustrative). The 5 Β°C rate is 37 Β°C rate / exp[(80000/8.314)(1/278 β 1/310)] β 0.50/35 = 0.014 dβ»ΒΉ, a tΒ½ of about 49 days in solution in the fridge. An NG-containing peptide reconstituted at neutral pH therefore loses percent-level purity per week even when refrigerated.
Diketopiperazine formation
Goolcharran and Borchardt showed that Xaa-Pro N-termini cyclize to diketopiperazine (DKP), cleaving off the N-terminal dipeptide. Kinetics were pseudo-first-order and depended on the unprotonated N-terminal amine (kinetic pKa 6.1). Phosphate buffer catalyzed the reaction, and the residue preceding Pro had a significant effect [17]. Any peptide with Pro at position 2 or 3 is a candidate. BPC-157 (GEPPPGKPADDAGLV) has Pro at positions 3β5; my inference is that the Glu-Pro N-terminal motif deserves DKP screening.
Do the incretins even have methionine? (Sequences checked)
The course assumption was that Met oxidation matters for the GLP-1/GIP/glucagon class. I checked actual sequences:
| Peptide | Sequence (one-letter; X = non-coded) | Met? | Trp? | Source |
|---|---|---|---|---|
| Semaglutide | H-Aib-EGTFTSDVSSYLEGQAA-K(lipid)-EFIAWLVRGRG | No | Yes (W31) | PubChem CID 56843331; Lau et al. [18] |
| Tirzepatide | YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPS | No | Yes | KEGG D11360 [20] |
| Retatrutide | YXQGTFTSDYSILLDKKAQXAFIEYLLEGGPSSGAPPPS | No | No | KEGG D12430 [20]; Coskun et al. [19] |
| Exenatide | HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NHβ | Yes (M14) | Yes (W25) | PubChem CID 45588096 |
| Native glucagon | HSQGTFTSDYSKYLDSRRAQDFVQWLMNT | Yes (M27) | Yes | UniProt P01275 (proglucagon) |
This was a real surprise, and it overturns part of the course framing. Retatrutide contains neither Met nor Trp. The Met27 of native glucagon and the Met14 of exendin-4 have been engineered out of these molecules, and in retatrutide the Trp has too. Semaglutide's Met-free GLP-1 backbone retains Trp31.
For these molecules, the oxidation-relevant residues are Trp (photo-oxidation, +4/+16/+32), Tyr, and His1 (MCO target). Exenatide is the Met case. Benet et al. found that exenatide was relatively stable at pH 4.5, 37 Β°C, and that "at pH 5.5β6.5, degradation was driven by oxidation, while driven by deamidation at pH 7.5β8.5" [21]. Note exenatide's Asn28βGly29: a textbook NG deamidation site, consistent with [15].
Thymosin Ξ²4 (UniProt P62328) has Met6 in the mature sequence (after initiator-Met removal). The short "TB-500" fragments sold in the research market usually don't include it, but which sequence a given supplier actually ships should be confirmed by MS.
Mitigation, ranked by mechanism
- Keep it dry and solid. Lyophilized powder slows all solution-phase pathways. Control residual moisture and use dried stoppers [13].
- Nitrogen or argon overlay plus verified CCI. This removes the terminal oxidant and is only worth anything if integrity is verified [14].
- Amber glass or opaque secondary packaging. It blocks the photo route, which matters most for Trp-containing incretins [9,12].
- Chelators (EDTA, DTPA) for metal-catalyzed routes. They work in many but not all systems; Li et al. found EDTA ineffective against ascorbate/Fe-driven oxidation [5]. Avoid adding reductants such as ascorbate without testing [1,5].
- Free L-methionine as a sacrificial scavenger in liquid formulations. Lam et al. found minimum effective protein:antioxidant molar ratios of 1:5 for methionine against temperature-induced oxidation [8].
- Low-peroxide excipient grades and peroxide testing of incoming surfactant/PEG lots [6,7].
- Avoid chloride + low pH + stainless steel contact in solution handling [8].
Detection: what the lab should run
- RP-HPLC/UPLC-UV with a gradient shallow enough to separate Met(O) diastereomers and Trp-oxidation products from the main peak.
- Intact LC-MS (ESI) to flag +16/+32/+4 and +1 (deamidation) species. Quantify by extracted-ion chromatogram, with caution about ionization-efficiency differences.
- MS/MS (peptide mapping or top-down for <5 kDa peptides) to localize the modification. This is essential for distinguishing Met(O) from hydroxy-Trp.
- Forced degradation panel to confirm the method is stability-indicating: 0.01β0.1% HβOβ (two-electron), AAPH (radical), FeΒ²βΊ/ascorbate (MCO), and light exposure (photo).
- Trace-metal screen (ICP-MS) on suspect lots and on reconstitution vehicles.
What this means for Peptide Partners
- CoAs should report oxidation-specific impurities, not just "purity β₯98%." For Met- or Trp-containing peptides, state the Met(O) or Trp-ox level by LC-MS, or at least state that the HPLC method resolves them, as shown by forced degradation.
- Ask suppliers: Is final fill under Nβ/Ar? Are vials CCI-tested, and by what method? What is the residual moisture spec? Are stoppers dried after sterilization? Are there stainless steel contact points in chloride/acidic solutions during purification? What is the counterion (TFA, acetate, HCl)?
- Product-specific risk triage: exenatide-class and glucagon-class (Met present) are high oxidation risk. Semaglutide and tirzepatide are Trp/photo-oxidation risks. Retatrutide's main risks are deamidation, aggregation and DKP, not oxidation. Spend analytical effort accordingly.
- Don't let marketing or CoAs claim "redox-stable" or cite electrochemical potentials. It isn't a valid predictor.
- Packaging: amber vials or cartons for Trp-containing products are cheap insurance against the light-driven pathway documented for compounded semaglutide [12].
- In-house capability target: UPLC-MS with MS/MS, a forced-degradation SOP, Karl Fischer, and headspace Oβ (laser) if volume justifies it. Otherwise outsource CCI.
Questions to bring to the lab
- On our current HPLC methods, do Met(O) diastereomers or Trp-ox species co-elute with the main peak? Has anyone run HβOβ and light forced degradation to prove the method is stability-indicating?
- For exenatide-class products, what Met(O) level do incoming lots show, and does it grow over 3 months at 25 Β°C?
- Is it worth sourcing a headspace Oβ analyzer, or should we audit suppliers' Nβ-overlay and CCI data and spot-check through a contract lab?
- Do any of our suppliers use stainless steel holding tanks for acidic chloride-containing peptide solutions? Should we ICP-MS a few lots for Fe/Cr/Ni/Cu?
- For semaglutide and tirzepatide, how much photo-degradation occurs under normal lab lighting over a week in clear vs amber glass, by LC-MS?
- Should NG-containing peptides carry an explicit "solution stability" caveat for researchers, given the 37 Β°C tΒ½ data from model peptides [15]?
- How do we confirm the actual sequence and modifications (lipidation, Aib, C-terminal amide) of incoming retatrutide/tirzepatide lots by MS, so the residue-level risk assessment is about the molecule we actually have?
What I still don't know
- I found no peer-reviewed forced-degradation study specifically on retatrutide or tirzepatide oxidation. My residue-based risk ranking is inference from sequence.
- How much metal is actually present in research-grade peptide lots, and whether SPPS/purification hardware leaches meaningfully, is undocumented in what I found. The stainless steel evidence [8] comes from an antibody formulation.
- The relative contribution of headspace Oβ vs residual peroxide vs metal to oxidation in a lyophilized research peptide stored dry has not, to my knowledge, been quantified.
- Whether Met(O) in exenatide-class peptides changes receptor activity enough to matter for research use is outside what I verified.
- Trp-oxidation product assignments (+4/+16/+32) are standard in the field, but I didn't verify a specific primary paper for them in this inquiry.
References
- Li S, SchΓΆneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: Mechanisms of oxidation and strategies for stabilization. Biotechnology and Bioengineering. 1995;48(5):490-500. doi:10.1002/bit.260480511
- Torosantucci R, SchΓΆneich C, Jiskoot W. Oxidation of Therapeutic Proteins and Peptides: Structural and Biological Consequences. Pharmaceutical Research. 2014;31(3):541-553. doi:10.1007/s11095-013-1199-9
- SchΓΆneich C. Methionine oxidation by reactive oxygen species: reaction mechanisms and relevance to Alzheimer's disease. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 2005;1703(2):111-119. doi:10.1016/j.bbapap.2004.09.009
- Stadtman ER. Metal ion-catalyzed oxidation of proteins: Biochemical mechanism and biological consequences. Free Radical Biology and Medicine. 1990;9(4):315-325. doi:10.1016/0891-5849(90)90006-5
- Li S, SchΓΆneich C, Wilson GS, Borchardt RT. Chemical Pathways of Peptide Degradation. V. Ascorbic Acid Promotes Rather than Inhibits the Oxidation of Methionine to Methionine Sulfoxide in Small Model Peptides. Pharmaceutical Research. 1993;10(11):1572-1579. doi:10.1023/a:1018960300769
- Kerwin BA. Polysorbates 20 and 80 Used in the Formulation of Protein Biotherapeutics: Structure and Degradation Pathways. Journal of Pharmaceutical Sciences. 2008;97(8):2924-2935. doi:10.1002/jps.21190
- Ha E, Wang W, Wang YJ. Peroxide formation in polysorbate 80 and protein stability. Journal of Pharmaceutical Sciences. 2002;91(10):2252-2264. doi:10.1002/jps.10216
- Lam XM, Yang JY, Cleland JL. Antioxidants for Prevention of Methionine Oxidation in Recombinant Monoclonal Antibody HER2. Journal of Pharmaceutical Sciences. 1997;86(11):1250-1255. doi:10.1021/js970143s
- Kerwin BA, Remmele RL. Protect from Light: Photodegradation and Protein Biologics. Journal of Pharmaceutical Sciences. 2007;96(6):1468-1479. doi:10.1002/jps.20815
- Enache TA, Oliveira-Brett AM. Boron doped diamond and glassy carbon electrodes comparative study of the oxidation behaviour of cysteine and methionine. Bioelectrochemistry. 2011;81(1):46-52. doi:10.1016/j.bioelechem.2011.02.001
- De Sciscio ML, Centola F, Saporiti S, D'Abramo M. Dissecting Methionine Oxidation by Hydrogen Peroxide in Proteins: Thermodynamics, Kinetics, and Susceptibility Descriptors. Journal of Chemical Information and Modeling. 2025;65(2):749-761. doi:10.1021/acs.jcim.4c01617
- Kopp KL, Lamberth K, Schelde O, Γgendahl AK, Wojcieszek M, Mogensen JE, RamΓrez-Andersen HS, Schneider CL, et al. Impurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists. Pharmaceutical Research. 2026;43(8):2861-2886. doi:10.1007/s11095-026-04146-9
- Pikal MJ, Shah S. Moisture transfer from stopper to product and resulting stability implications. Dev Biol Stand. 1992;74:165-177. PMID:1592166
- Victor KG, Levac L, Timmins M, Veale J. Method Development for Container Closure Integrity Evaluation via Headspace Gas Ingress by Using Frequency Modulation Spectroscopy. PDA Journal of Pharmaceutical Science and Technology. 2017;71(6):429-453. doi:10.5731/pdajpst.2017.007518
- Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. Journal of Biological Chemistry. 1987;262(2):785-794. doi:10.1016/S0021-9258(19)75855-4
- Robinson NE, Robinson AB. Molecular clocks. Proceedings of the National Academy of Sciences. 2001;98(3):944-949. doi:10.1073/pnas.98.3.944
- Goolcharran C, Borchardt RT. Kinetics of Diketopiperazine Formation Using Model Peptides. Journal of Pharmaceutical Sciences. 1998;87(3):283-288. doi:10.1021/js970325m
- Lau J, Bloch P, SchΓ€ffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00726
- Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O'Farrell LS, Briere DA, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234-1247.e9. doi:10.1016/j.cmet.2022.07.013
- KEGG DRUG database. D12430 Retatrutide (USAN); D11360 Tirzepatide. Kanehisa Laboratories. https://www.kegg.jp/entry/D12430 ; https://www.kegg.jp/entry/D11360
- Benet A, Halseth T, Kang J, Kim A, Ackermann R, Srinivasan S, Schwendeman S, Schwendeman A. The Effects of pH and Excipients on Exenatide Stability in Solution. Pharmaceutics. 2021;13(8):1263. doi:10.3390/pharmaceutics13081263